<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00905073</url>
  </required_header>
  <id_info>
    <org_study_id>10988</org_study_id>
    <nct_id>NCT00905073</nct_id>
  </id_info>
  <brief_title>Low Dose Cyclosporin and Methotrexate Therapy in Diabetes</brief_title>
  <official_title>Low Dose Cyclosporin and Methotrexate Therapy in New Onset Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Georgetown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Georgetown University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether treatment with low dose cyclosporin and
      methotrexate can inhibit the development of new onset diabetes mellitus
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: Although high doses of cyclosporin (cyclo) inhibits the development of type 1
      diabetes mellitus, its usefulness is limited by its toxicity. Since methotrexate (mtx) and
      cyclo synergistically inhibit other disease processes, we hypothesized that low dose cyclo
      and mtx therapy could safely induce remission.

      Research Design and Methods: In an open pilot study, insulin dose and glycemic control will
      be compared in children with new onset Type 1 diabetes administered cyclo at 7.5 mg/kg/day
      for 6 weeks and then 4 mg/kg/day and mtx 5 mg/kg/day for one year with control children.
      After 6 weeks, doses were adjusted to maintain blood cyclo levels to 100-200 ng/ml.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 1990</start_date>
  <completion_date type="Actual">June 1994</completion_date>
  <primary_completion_date type="Actual">June 1994</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>insulin dose</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>renal function</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>cyclosporin+Methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cyclosporin treatment at 7.5 mg/kg/day for 6 weeks and then 4 mg/kg/day for on year and methotrexate 5 mg/kg/day for one year.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporin and methotrexate</intervention_name>
    <description>cyclosporin 7.5 mg/kg/day for 6 weeks and then 4 mg/kg/day for one year and methotrexate 5 mg/kg/day for one year. After 6 weeks, cyclosporin doses will adjusted to maintain blood cyclo levels to 100-200 ng/ml.</description>
    <arm_group_label>cyclosporin+Methotrexate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Type1 diabetes mellitus and be obtaining insulin therapy for less than 4
             weeks

        Exclusion Criteria:

          -  Ketoacidosis

          -  Body weight over 110% of ideal weight

          -  Condition where immunosuppression is contraindicated

          -  Abnormal liver or renal function tests
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas Sobel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Georgetown University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington DC</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2009</study_first_submitted>
  <study_first_submitted_qc>May 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2009</study_first_posted>
  <last_update_submitted>April 12, 2011</last_update_submitted>
  <last_update_submitted_qc>April 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 13, 2011</last_update_posted>
  <responsible_party>
    <name_title>Douglas Sobel</name_title>
    <organization>Georgetown University</organization>
  </responsible_party>
  <keyword>type 1 diabetes mellitus</keyword>
  <keyword>cyclosporin</keyword>
  <keyword>methotrexate</keyword>
  <keyword>renal function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

